African American and Hispanic women in the United States and Europe, have 25-OH-D concentrations <20 ng/ mL (50 nmol/L), 9 a value set for the basis of the Recommended Dietary Allowance. 1 However, in utero, skeletal mineralization is primarily independent of maternal vitamin D status, making the clinical significance of 25-OH-D concentrations during pregnancy unclear. 10, 11 
EFFECTS OF PRETERM BIRTH ON MINERAL METABOLISM
Population-based studies of rickets among preterm infants are lacking; therefore, the frequency is not known or reliably estimated. Approximately 10% to 20% of hospitalized infants with birth weight <1000 g have radiographically defined rickets (metaphyseal changes) despite current nutritional practices. 12 This frequency is much lower than the 50% incidence in this population described before fortification of human milk and the use of preterm high mineral containing formulas were routine. 13 One challenge in identifying the prevalence of rickets is the confusion related to terminology. Rickets is defined by radiographic findings, not by any biochemical findings. Standard radiographic definitions of rickets are used. Poorly defined terms, such as osteopenia or biochemical rickets, are often used in the literature interchangeably with radiographically defined rickets. Rickets is not widely reported in preterm infants with birth weight >1500 g unless there are health issues severely limiting enteral nutrition.
Limited long-term studies of bone mineralization exist in former preterm infants. In general, these studies do not demonstrate significant long-term negative effects on bone health in preterm infants who demonstrate catch-up growth occurring during the first 2 years after birth. 14 A single study demonstrated a small decrease in young adolescent height when the alkaline phosphatase concentration exceeded 1200 IU/L. 15 That study was limited because of the use of formulas containing relatively low amounts of energy and protein. The preterm infants had reduced adult height and low lumbar spine bone mineral density compared with population reference data, and the deficits were greatest in those with birth weight <1200 g and those born small for gestational age. 16 One study indicated a significant decrease in height during the prepubertal years of former very low birth weight (VLBW) infants exposed to dexamethasone for the treatment of bronchopulmonary dysplasia. 17 In addition, Dalziel et al 18 demonstrated that prenatal steroid use did not affect peak bone mass. It appeared that slower fetal growth, rather than preterm birth, predicted lower peak bone mass. The lower peak bone mass in those born small for gestational age was appropriate for their adult height.
IN-HOSPITAL ASSESSMENT AND MANAGEMENT
A summary of high-risk factors for the development of rickets is shown in Table 1. It is common medical practice to assess VLBW infants biochemically for evidence of abnormalities of bonerelated parameters, especially the serum alkaline phosphatase activity (APA) and serum phosphorus concentration, and subsequently to evaluate them radiographically if these evaluations suggest a high risk of developing rickets. No absolute values for a low serum phosphorus concentration exist, with values below ∼4 mg/dL often, but not always, being considered associated with low phosphorus status. On the other hand, there is little, if any, evidence supporting measuring bone mineral-related laboratory values in infants with birth weight >1500 g unless infants are unable to achieve full feeds or have other conditions, such as severe cholestasis or renal disease, placing them at risk for bone loss.
Typically, a very high serum APA (>1000 IU/L) is suggestive, but not proof, of rickets. In 1 study, values >1000 IU/L were associated with an incidence of radiologic rickets of ∼50% to 60%, 12 although some cases were also seen with serum APA in the range of 800 to 1000 IU/L. Elevations of serum APA and clinical rickets are uncommon in the first 4 weeks after birth at any gestational age. Therefore, screening the serum APA and serum phosphorus at 4 to 6 weeks after birth in VLBW infants followed by biweekly monitoring is appropriate. Typically, the APA will peak at 400 to 800 IU/L and then decrease in VLBW infants who do not develop rickets. In this circumstance, clinical experience indicates that if the infant has APA values in this range and has achieved full feeds of human milk with a mineral-containing fortifier or formula designed for preterm infants, there is minimal, if any, risk of developing rickets, and measurement of APA can usually be stopped. Other markers of bone status include serum osteocalcin concentration and bone-specific APA; the latter has been considered of value in cases of cholestasis to help identify the bonerelated fraction from total APA. At present, there are no data demonstrating clinical utility of measuring serum osteocalcin concentration and bone-specific APA in neonates, and normal values do not exist for preterm infants. Backstrom et al 19 found no additional information gained from measurement of bone-specific APA compared with total APA in preterm infants. It is, therefore, unlikely that these laboratory values, which are poorly standardized in neonates and expensive to obtain, will be a substantial aspect of clinical decisionmaking in an individual infant.
The ultimate diagnosis of rickets requires a radiographic evaluation, usually of either the wrist or the knee. Chest radiographs revealing abnormalities of the ribs may be suggestive of rickets, but a confirmatory longbone film of the wrist or knee should be obtained to confirm the diagnosis. The radiologist should categorize the infant as likely having or not having rickets. Nonspecific terms, such as "osteopenia" or "washed out bones," have little clinical meaning. Rickets in preterm infants appears radiographically similar to rickets in older infants and should be characterized as such. The use of either bone ultrasonography or, before discharge, dual energy radiographic absorptiometry to evaluate bone status may be considered. However, the lack of data related to normal values in former preterm infants indicate that these are performed primarily for research purposes. Current data do not support routine use of any of these techniques for preterm infants, including those with abnormal radiographic findings.
CALCIUM AND PHOSPHORUS INTAKE AND ABSORPTION
Rickets in preterm infants is almost always attributable to decreased total absorbed calcium and phosphorus. Decreases in absorption can result from either low intake or low absorption efficiency. 20 Several studies have revealed that, in healthy preterm infants, calcium absorption averages ∼50% to 60% of intake, [21] [22] [23] [24] which is similar to that of breastfed full-term infants. 1 In contrast, phosphorus absorption is typically 80% to 90% of dietary intake. 23 Unfortified human milk, parenteral nutrition, and infant formulas designed for full-term infants, including amino acid-based and soy-based formulas, do not contain enough calcium and phosphorus to fully meet the needs for bone mineralization in preterm infants. Even at very high rates of absorption (eg, 80% or more), the calcium and phosphorus intakes from unfortified human milk or formulas not intended for preterm infants would be a limiting factor in bone growth. 20 Table 2 provides sample numbers for the intake, absorption, and retention of calcium in a VLBW infant fed fortified human milk or a formula for preterm infants typically used in the United States compared with unfortified human milk.
Although most attention is focused on calcium intake, the very high urinary calcium concentrations found in preterm infants fed unfortified human milk suggests that phosphorus deficiency is at least as important, if not more important, than calcium deficiency in the etiology of this disease. 4, 25, 26 Some cases of hypercalcemia have been reported in preterm infants fed unfortified human milk as a result of the very low phosphorus content and resultant relative excess of calcium. 27 
VITAMIN D IN PRETERM INFANTS
Vitamin D enhances the absorption of calcium, and in general, calcium absorption efficiency is greater in people whose calcium intake is low and in whom vitamin D-dependent absorption increases. However, in preterm infants, the calcium absorption fraction appears to be relatively constant across a wide range of intakes. It has been suggested 21 that most calcium absorption may not be vitamin D dependent in preterm infants in the first month after birth but rather occurs primarily via a passive, paracellular absorption. This hypothesis is unproven, however, and the exact timing and proportion of vitamin D-dependent absorption of calcium and phosphorus in preterm infants is unknown. Some older data suggest an effect of highdose vitamin D on calcium absorption, but these data have not been verified by using isotopic techniques nor performed on groups of infants using currently available high mineralcontaining diets. 5 The basic approach to prevention of rickets in preterm infants is the use of diets containing high amounts of minerals. In almost all infants with birth weight <1800 to 2000 g, regardless of gestational age, it is recommended to use formulas designed for preterm infants or human milk supplemented with fortifiers designed for use in this population. Bone mineral content is low in infants who are small for gestational age, leading to the recommendation to use these products on the basis of weight rather than gestational age. 31 Further research is needed, however, to clarify whether this is appropriate practice for all preterm infants with birth weight <2000 g.
In the United States, fortified human milk and formulas designed for preterm infants provide calcium intakes of ∼180 to 220 mg/kg per day and approximately half that amount of phosphorus (Table 3) . Two widely used sets of recommendations in the United States from Tsang et al 32 and Klein et al 33 (Table 4) are consistent with these intakes, and for calcium, it is reasonable to adopt the lower value and the higher value of the 2 as a range for recommended intakes (ie, 150 to 220 mg/kg per day). For phosphorus, the lower value of 60 mg/kg per day would lead to a 2:1 ratio or higher with the recommended calcium intakes, and thus, a minimum lower intake level of 75 mg/kg per day is recommended to provide a calcium-tophosphorous ratio less than 2:1. Although no optimal calcium-to-phosphorous ratio is identified, generally a 1.5 to 1.7:1 ratio may be optimal for preterm infants. 34 For an upper intake recommendation for phosphorous, the higher value of 140 mg/kg per day is suggested. As noted later, phosphorus deficiency may occur in some preterm infants, and thus, a higher upper level recommendation is provided.
Pending further research, using the full-term infant vitamin D intake recommendation of 400 IU/day is appropriate for preterm infants born with birth weight >1500 g. Potential risks related to high 25-OH-D concentrations are unknown, and the established upper tolerable intake of 1000 IU/day for healthy full-term infants may be considered an upper intake for preterm infants as well. For VLBW infants, few data are available. Their smaller size may lead to a lower need for vitamin D to achieve adequate 25-OH-D concentrations, 28, 29 but further data are needed on this relationship. On the basis of limited data, a vitamin D intake of 200 to 400 IU/day for VLBW infants is recommended. This intake should be increased to 400 IU/day when weight exceeds ∼1500 g and the infant is tolerating full enteral nutrition. Because this would require supplemental vitamins being added in addition to available human milk fortifiers, some may wish to wait until weight is closer to 2000 g to provide a full 400 IU/day because of concern about the osmolarity of vitamin supplements. These intake recommendations should be subject to clinical trials with rickets and fractures as clinical outcomes.
Comparisons With Other Recommendations
In Europe, a considerably lower target for calcium and phosphorus intake is common (Table 4) . European guidelines generally suggest higher intakes of vitamin D of 800 to 1000 IU/day, 4,5 but there is no direct comparison of this approach compared with the approach used in the United States. Although this vitamin D intake is likely safe and is within the tolerable upper intake limit of the IOM for full-term infants, 1 no data are available for groups of VLBW infants and especially infants with birth weight <1000 g to assess the safety of providing these vitamin D intakes, which, on a bodyweight basis may be 5 to 10 times the amount recommended for full-term neonates.
As noted by the IOM report, 1 
OTHER MANAGEMENT ISSUES
Despite the use of feedings with high mineral content, some infants may develop rickets. The management of infants who have rickets and remain dependent on intravenous nutrition is beyond the scope of this review, but in general, maximizing calcium and phosphorus intake from intravenous nutrition while minimizing factors that lead to mineral loss (steroids, some diuretics) is advised. Management approaches for infants who are fed enterally are described in Table 5 .
These principles have not been tested in controlled trials but reflect expert opinion related to mineral intake and metabolism.
Whether minerals should be added directly to human milk separate from the use of human milk fortifiers is controversial. This practice has been advocated, combined with monitoring of urinary calcium and phosphorus. 36 Although shown to be effective in some small studies, adding minerals directly to human milk, especially in the absence of using human milk fortifiers, is not widely performed in the United States for routine management of VLWB infants, because individually supplementing these minerals does not also provide the extra protein and other nutrients needed for growth.
However, in some infants who have evidence of rickets, the need for fluid restriction or inability to tolerate formula designed for preterm infants or human milk fortifier may lead to the need to directly supplement calcium and phosphorus. Optimal or safest forms and doses of calcium and phosphorus to add directly to the diet of preterm infants are unknown. In general, most widely used is calcium glubionate, a liquid form of calcium A special population is older preterm infants who develop a low serum phosphorus concentration, often in conjunction with a serum APA <500 IU/L. The specific cause of this low serum phosphorus concentration is unknown, but it is likely partly related to the use of phosphorus in nonbone tissue, such as muscle. The exact serum phosphorus concentration for which evidence demonstrates a need to supplement phosphorus without calcium is not known, but a serum concentration below ∼4.0 mg/dL, especially if present for more than 1 to 2 weeks, suggests consideration of adding phosphorus directly.
An ideal oral form of phosphorus for use in preterm infants does not exist. Administering the intravenous preparations orally can be considered, because they are lower in osmolarity than are commercially available phosphorus-containing liquids. For example, potassium phosphate provides 31 mg of elemental phosphorus per millimole, and a dose of 10 to 20 mg/kg per day of elemental phosphorus is reasonable and will likely resolve hypophosphatemia in most preterm infants.
Transitioning Off High-Mineral Containing Products
Decreasing mineral intake, by either using less human milk fortifier or discontinuing the use of formulas for preterm infants, is often begun at a body weight of ∼2000 g. Delaying the switch to transitional formulas and continuing the use of formula designed for preterm infants or human milk fortifier should be considered for infants on fluid restriction, especially <150 mL/kg per day, or for infants with a prolonged course of parenteral nutrition and a persistent elevation of serum APA (ie, >800 IU/L). Use of formula designed for preterm infants would likely be safe until body weight of at least 3000 g is reached, after which some concern might be present about vitamins or minerals (especially vitamin A) exceeding the established tolerable upper intake levels. 37 No clinical evidence of vitamin A toxicity exists, although for intakes slightly above the upper level, a riskbenefit assessment may need to be performed regarding use of formulas designed for preterm infants in some larger infants.
Preterm infants who do not tolerate cow milk protein or lactose-containing products represent a special circumstance. Amino acid-based, soy-based, and other specialized infant formulas generally have higher levels of minerals than do routine infant formulas, but the bioavailability of these minerals, especially in high-risk infants such as those with a history of feeding intolerance or intestinal failure, is uncertain. As such, biochemical monitoring may need to be continued for an extended period of time, and in some cases, direct supplementation with added minerals should be considered.
POSTDISCHARGE MANAGEMENT OF PRETERM INFANTS
VLBW infants who are discharged exclusively breastfeeding will often do well from a bone mineral perspective; however, they may be at risk for a very high serum APA after discharge. No data are available to define the length of time exclusively breastfed infants receiving such formula supplements or transitional formula need to continue them. This decision is often driven by growth in weight, head circumference, and length, not by bone mineral concerns. Infants consuming less than ∼800 mL of currently marketed transitional formula daily after discharge from the hospital will receive <400 IU/day of vitamin D for several weeks to several months. It is reasonable to supplement these infants with a small amount of vitamin D (often 200 to 400 IU/day) to ensure a total intake of at least 400 IU/day.
From a bone mineral perspective, infants with birth weight 1500 to 2000 g will generally do well with exclusive breastfeeding or routine infant formula after discharge from the hospital. Some pediatricians choose to use a transitional infant formula after infants reach ∼34 weeks' postmenstrual age or ∼1800 to 2000 g body weight.
There are no specific studies related to the bone mineral needs of infants who are "late preterm" (ie, 34-36 weeks' gestation and >2000 g at birth). However, there are no clinical reports of mineral deficiency or rickets in this population whether breastfed exclusively or fed formula designed for preterm infants, as long as long-term vitamin D status is adequate. Therefore, it is likely that late preterm infants do not generally need special management related to bone minerals after discharge from the hospital. Breastfed preterm infants who are at home should receive 400 IU/day of vitamin D. Formula-fed preterm infants receiving formulas designed for fullterm infants would generally not achieve an intake of 400 IU/day of vitamin D until consuming ∼800 mL of formula daily, depending on the formula. Providing these infants with an additional 200 to 400 IU/day may be considered, but there are no data indicating any clinical benefit to this practice.
Small-for-gestational-age infants at or near term, such as is common in many global settings, may usually be provided minerals in the same way as larger infants of the same gestational age. Such infants should be monitored carefully for growth, and an adequate intake of vitamin D should be ensured.
SUMMARY
1. Preterm infants, especially those <27 weeks' gestation or with birth weight <1000 g with a history of multiple medical problems, are at high-risk of rickets.
2. Routine evaluation of bone mineral status by using biochemical testing is indicated for infants with birth weight <1500 g but not those with birth weight >1500 g. Biochemical testing should usually be started 4 to 5 weeks after birth.
3. Serum APA >800 to 1000 IU/L or clinical evidence of fractures should lead to a radiographic evaluation for rickets and management focusing on maximizing calcium and phosphorus intake and minimizing factors leading to bone mineral loss.
4.
A persistent serum phosphorus concentration less than ∼4.0 mg/dL should be followed, and consideration should be given for phosphorus supplementation.
5. Routine management of preterm infants, especially those with birth weight <1800 to 2000 g, should include human milk fortified with minerals or formulas designed for preterm infants (see Table 4 for details).
6. At the time of discharge from the hospital, VLBW infants will often be provided higher intakes of minerals than are provided by human milk or formulas intended for term infants through the use of transitional formulas. If exclusively breastfed, a follow-up serum APA at 2 to 4 weeks after discharge from the hospital may be considered.
7. When infants reach a body weight >1500 g and tolerate full enteral feeds, vitamin D intake should generally be ∼400 IU/day, up to a maximum of 1000 IU/day.
